Glenn S Tillotson PhD, FIDSA

Although antibiotics are the standard-of-care treatment for Clostridioides difficile infection, they can cause further microbiota changes that predispose patients to recurrence.

Rebyota is a live biotherapeutic product that is unfamiliar to many pharmacists and other health care providers with different steps in the eventual administration process.

The relative abundance of gram-negative Bacteroidetes to other phyla, such as gram-positive Firmicutes, is essential to maintain biodiversity and human gut health.

Fecal microbiota transplantation is proving to be an effective treatment for many patients with specific disorders associated with dysbiosis.

From an economic perspective, C. difficile has a staggering financial impact on the US health care system, as well on the patients infected.

Approximately 450,000 cases of Clostridioides difficile infection occur each year in the United States and approximately 25% of patients treated for an initial episode will experience recurrence.